

Accepted Manuscript

Strategies for ribavirin prodrugs delivery systems for reducing the side-effect hemolysis enhancing their therapeutic effect

Haiyan Guo, Shuai Sun, Zhenhua Yang, Xing Tang, Yanjiao Wang

PII: S0168-3659(15)00234-5
DOI: doi: [10.1016/j.jconrel.2015.04.016](https://doi.org/10.1016/j.jconrel.2015.04.016)
Reference: COREL 7637

To appear in: *Journal of Controlled Release*

Received date: 30 January 2015
Revised date: 8 April 2015
Accepted date: 12 April 2015



Please cite this article as: Haiyan Guo, Shuai Sun, Zhenhua Yang, Xing Tang, Yanjiao Wang, Strategies for ribavirin prodrugs delivery systems for reducing the side-effect hemolysis enhancing their therapeutic effect, *Journal of Controlled Release* (2015), doi: [10.1016/j.jconrel.2015.04.016](https://doi.org/10.1016/j.jconrel.2015.04.016)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect

Haiyan Guo^a, Shuai Sun^a, Zhenhua Yang^a, Xing Tang^a, Yanjiao Wang^a

^a Department of Pharmaceutics, College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China

Abstract

Ribavirin is a nucleoside which is used as an antiviral agent against both RNA and DNA viruses. However, accumulation in erythrocytes causes hemolysis which limits its usefulness. To minimize ribavirin-induced hemolysis and increase its antiviral effect, considerable efforts have been made involving chemical prodrugs and various formulations. Combination with macromolecules to achieve better targeting and increased uptake is one of the most promising strategies. In addition, decreasing the association with RBCs through prodrugs and delivery systems is considered. This review summarizes prodrugs and delivery systems for ribavirin and, at the same time examines these different strategies. Moreover, a novel design of prodrug is proposed for further study.

Keyword: ribavirin; hemolysis; antiviral effect; prodrug; delivery system

1. Introduction

Ribavirin(1-b-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), a synthetic nucleoside, exhibits a broad spectrum of activity against DNA and RNA viruses¹, mainly including respiratory syncytial virus² and lassa fever virus³, in addition to its combination with peg-interferon, a standard therapy for chronic Hepatitis C^{1, 4} in clinical situations. The FDA approved treatment for chronic hepatitis C virus (HCV) is the combination of pegylated interferon- α (IFN), ribavirin and protease inhibitors such as boceprevir and telaprevir⁵. With the advent of direct-acting antiviral (DAA)

Download English Version:

<https://daneshyari.com/en/article/7863253>

Download Persian Version:

<https://daneshyari.com/article/7863253>

[Daneshyari.com](https://daneshyari.com)